Search

Shahla Maryam Jamzad

age ~60

from Belmont, MA

Get Report
Also known as:
  • Shahla M Jamzad
  • Shahla Jamzad Behta
  • Hahla Jamzad
  • Jamzad Shahla
Phone and address:
4 Lorimer Rd, Belmont, MA 02478
Related to:
Connected to:

Shahla Jamzad Phones & Addresses

  • 4 Lorimer Rd, Belmont, MA 02478
  • Watertown, MA
  • Cambridge, MA
  • Conshohocken, PA
  • Ardmore, PA

Work

  • Company:
    Sunovion pharmaceuticals inc.
    Dec 2014
  • Position:
    Director, formulation development at sunovion pharmaceuticals inc

Education

  • Degree:
    Doctorates, Doctor of Pharmacy
  • School / High School:
    Daneshgahe Oloom Pezeshki Va Khadamat Behdashti Darmani Iran
  • Specialities:
    Pharmacy

Skills

Formulation • Drug Development • Technology Transfer • Gmp • Drug Discovery • Pharmacokinetics • Drug Delivery • Ind • Pharmaceutical Industry • Biotechnology • Clinical Trials • Quality By Design • Pharmaceutics • Project Management • Cross Functional Communication • Teamwork • Organization Skills • Leadership • Formulation Development • Research and Development • Technical Team Leadership • Technical Transfer and Cmo Oversight • Regulatory Cmc Writing • New Drug Application • Cmc Team Leadership

Industries

Pharmaceuticals

Us Patents

  • Pharmaceutical Composition And Administrations Thereof

    view source
  • US Patent:
    20130224293, Aug 29, 2013
  • Filed:
    Feb 27, 2013
  • Appl. No.:
    13/779654
  • Inventors:
    VERTEX PHARMACEUTICALS INCORPORATED - , US
    SHAHLA JAMZAD - BELMONT MA, US
    MAJED FAWAZ - FOXBORO MA, US
    LAURA DAS - CHARLESTOWN MA, US
    CHONG-HUI GU - WABAN MA, US
    PATRICIA NELL HURTER - HARVARD MA, US
    MEGHNA JAI ISRANI - BOSTON MA, US
    MEGHAN M. JOHNSTON - WAKEFIELD MA, US
    DRAGUTIN KNEZIC - WATERTOWN MA, US
    ANDREW G. KUZMISSION - SHREWSBURY MA, US
    HONGREN WANG - LEXINGTON MA, US
  • Assignee:
    VERTEX PHARMACEUTICALS INCORPORATED - CAMBRIDGE MA
  • International Classification:
    A61K 31/47
  • US Classification:
    424464, 514312
  • Abstract:
    The present invention relates to pharmaceutical compositions containing a solid dispersion of N—[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.

  • Pharmaceutical Composition And Administrations Thereof

    view source
  • US Patent:
    20120064157, Mar 15, 2012
  • Filed:
    Aug 26, 2011
  • Appl. No.:
    13/219590
  • Inventors:
    Eleni Dokou - Cambridge MA, US
    Shahla Jamzad - Belmont MA, US
  • Assignee:
    Vertex Pharmaceuticals Incorporated - Cambridge MA
  • International Classification:
    A61K 9/20
    A61P 11/06
    A61P 43/00
    A61P 11/00
    A61P 11/02
    A61P 1/00
    A61P 1/18
    A61P 15/08
    A61P 1/16
    A61P 7/00
    A61P 3/00
    A61P 3/06
    A61P 7/02
    A61P 3/10
    A61P 5/18
    A61P 35/00
    A61P 5/14
    A61P 19/08
    A61P 25/28
    A61P 25/16
    A61P 25/00
    A61P 27/02
    A61P 19/10
    A61K 31/47
  • US Classification:
    424465, 514312
  • Abstract:
    The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders and mini-tablets and methods for treating cystic fibrosis employing the pharmaceutical composition.

  • Salts, Crystal Forms, And Production Methods Thereof

    view source
  • US Patent:
    20220402937, Dec 22, 2022
  • Filed:
    Jul 22, 2022
  • Appl. No.:
    17/814378
  • Inventors:
    - Marlborough MA, US
    Nandkumar Nivritti BHOGLE - Shrewsbury MA, US
    Xiaoxia CHEN - Acton MA, US
    Shahla JAMZAD - Belmont MA, US
    Robert Joseph PRYTKO - Millbury MA, US
    Kostas SARANTEAS - Littleton MA, US
    Michael Joseph SIZENSKY - South Grafton MA, US
    Harold Scott WILKINSON - Westboro MA, US
    Haitao ZHANG - Shrewsbury MA, US
  • Assignee:
    Sunovion Pharmaceuticals Inc. - Marlborough MA
  • International Classification:
    C07D 495/04
    A61P 25/18
    A61K 9/20
    A61K 45/06
    A61K 31/381
    A61P 25/00
  • Abstract:
    Provided are salts of (S)-(4,5-dihydro-7H-thieno[2,3-c]pyran-7-yl)-N-methylmethanamine and various of crystal forms thereof, and compositions, medicaments, pharmaceutically acceptable formulations thereof, and methods of making same. In addition, provided are compounds comprising specific particle size distributions of crystalline (S)-(4,5-dihydro-7H-thieno[2,3-c]pyran-7-yl)-N-methylmethanamine HCl and methods of making and modulating the particle size distributions.

  • Pharmaceutical Composition And Administrations Thereof

    view source
  • US Patent:
    20220241206, Aug 4, 2022
  • Filed:
    Sep 15, 2021
  • Appl. No.:
    17/475622
  • Inventors:
    - Boston MA, US
    Shahla JAMZAD - Belmont MA, US
    Majed FAWAZ - Foxboro MA, US
    Laura DAS - Charlestown MA, US
    Chong-Hui GU - Waban MA, US
    Patricia Nell HURTER - Harvard MA, US
    Meghna Jai ISRANI - Boston MA, US
    Meghan M. JOHNSTON - Wakefield MA, US
    Dragutin KNEZIC - Watertown MA, US
    Andrew G. KUZMISSION - Shrewsbury MA, US
    HongRen WANG - Lexington MA, US
  • Assignee:
    Vertex Pharmaceuticals Incorporated - Boston MA
  • International Classification:
    A61K 9/20
    A61K 31/47
    A61K 9/16
    A61K 9/48
    C07D 215/56
    A61K 9/14
    A61K 47/02
    A61K 47/12
    A61K 47/20
    A61K 47/26
    A61K 47/38
  • Abstract:
    The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.

  • Salts, Crystal Forms, And Production Methods Thereof

    view source
  • US Patent:
    20210053983, Feb 25, 2021
  • Filed:
    Aug 28, 2020
  • Appl. No.:
    17/006101
  • Inventors:
    - Marlborough MA, US
    Nandkumar Nivritti BHOGLE - Shrewsbury MA, US
    Xiaoxia CHEN - Acton MA, US
    Shahla JAMZAD - Belmont MA, US
    Robert Joseph PRYTKO - Millbury MA, US
    Kostas SARANTEAS - Littleton MA, US
    Michael Joseph SIZENSKY - South Grafton MA, US
    Harold Scott WILKINSON - Westboro MA, US
    Haitao ZHANG - Shrewsbury MA, US
  • Assignee:
    Sunovion Pharmaceuticals Inc. - Marlborough MA
  • International Classification:
    C07D 495/04
    A61P 25/18
    A61K 9/20
    A61K 45/06
    A61K 31/381
    A61P 25/00
  • Abstract:
    Provided are salts of (S)-(4,5-dihydro-7H-thieno[2,3-c]pyran-7-yl)-N-methylmethanamine and various of crystal forms thereof, and compositions, medicaments, pharmaceutically acceptable formulations thereof, and methods of making same. In addition, provided are compounds comprising specific particle size distributions of crystalline (S)-(4,5-dihydro-7H-thieno[2,3-c]pyran-7-yl)-N-methylmethanamine HCl and methods of making and modulating the particle size distributions.

  • Oral Dosage Forms

    view source
  • US Patent:
    20200405867, Dec 31, 2020
  • Filed:
    Jan 18, 2019
  • Appl. No.:
    16/963116
  • Inventors:
    - Marlborough MA, US
    Shahla JAMZAD - Belmont MA, US
  • Assignee:
    Sunovion Pharmaceuticals Inc. - Marlborough MA
  • International Classification:
    A61K 47/40
    A61K 9/00
    A61K 31/136
    A61K 47/12
    A61K 47/26
  • Abstract:
    The present application generally relates to pharmaceutical compositions comprising dasotraline, and methods of using the pharmaceutical compositions thereof to treat disorders, while limiting a perceived bitter taste or paresthesic sensation.

  • Pharmaceutical Composition And Administrations Thereof

    view source
  • US Patent:
    20190274959, Sep 12, 2019
  • Filed:
    Mar 12, 2019
  • Appl. No.:
    16/299675
  • Inventors:
    - Boston MA, US
    Shahla JAMZAD - Belmont MA, US
    Majed FAWAZ - Foxboro MA, US
    Laura DAS - Charlestown MA, US
    Chong-Hui GU - Waban MA, US
    Patricia Nell HURTER - Harvard MA, US
    Meghna Jai ISRANI - Boston MA, US
    Meghan M. JOHNSTON - Wakefield MA, US
    Dragutin KNEZIC - Watertown MA, US
    Andrew G. KUZMISSION - Shrewsbury MA, US
    HongRen WANG - Lexington MA, US
  • Assignee:
    Vertex Pharmaceuticals Incorporated - Boston MA
  • International Classification:
    A61K 9/20
    A61K 31/47
    A61K 9/16
    A61K 9/14
    A61K 47/02
    A61K 47/38
    A61K 47/20
    A61K 47/26
    A61K 9/48
    C07D 215/56
    A61K 47/12
  • Abstract:
    The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.

  • Salts, Crystal Forms, And Production Methods Thereof

    view source
  • US Patent:
    20190256525, Aug 22, 2019
  • Filed:
    Feb 15, 2019
  • Appl. No.:
    16/277443
  • Inventors:
    - Marlborough MA, US
    Nandkumar Nivritti Bhogle - Shrewsbury MA, US
    Xiaoxia Chen - Acton MA, US
    Shahla Jamzad - Belmont MA, US
    Robert Joseph Prytko - Millbury MA, US
    Kostas Saranteas - Littleton MA, US
    Harold Scott Wilkinson - Westboro MA, US
    Haitao Zhang - Shrewsbury MA, US
  • International Classification:
    C07D 495/04
    A61P 25/18
    A61K 9/20
  • Abstract:
    Provided are salts of (S)-(4,5-dihydro-7H-thieno[2,3-c]pyran-7-yl)-N-methylmethanamine and various of crystal forms thereof, and compositions, medicaments, pharmaceutically acceptable formulations thereof, and methods of making same. In addition, provided are compounds comprising specific particle size distributions of crystalline (S)-(4,5-dihydro-7H-thieno[2,3-c]pyran-7-yl)-N-methylmethanamine HCl and methods of making and modulating the particle size distributions.

Resumes

Shahla Jamzad Photo 1

Director, Formulation Development At Sunovion Pharmaceuticals Inc

view source
Location:
Belmont, MA
Industry:
Pharmaceuticals
Work:
Sunovion Pharmaceuticals Inc.
Director, Formulation Development at Sunovion Pharmaceuticals Inc
Sunovion Pharmaceuticals Inc. Mar 2014 - Nov 2014
Senior Formulation Consultant
Vertex Pharmaceuticals Jun 2012 - Nov 2013
Senior Scientist, Formulation Development Department
Vertex Pharmaceuticals Apr 2009 - Jun 2012
Scientist Ii , Formulation Development Department
Vertex Pharmaceuticals Jul 2006 - Apr 2009
Scientist I, Formulation Development Department
Education:
Daneshgahe Oloom Pezeshki Va Khadamat Behdashti Darmani Iran
Doctorates, Doctor of Pharmacy, Pharmacy Temple University
Doctorates, Doctor of Philosophy, Philosophy
Skills:
Formulation
Drug Development
Technology Transfer
Gmp
Drug Discovery
Pharmacokinetics
Drug Delivery
Ind
Pharmaceutical Industry
Biotechnology
Clinical Trials
Quality By Design
Pharmaceutics
Project Management
Cross Functional Communication
Teamwork
Organization Skills
Leadership
Formulation Development
Research and Development
Technical Team Leadership
Technical Transfer and Cmo Oversight
Regulatory Cmc Writing
New Drug Application
Cmc Team Leadership
Get Report for Shahla Maryam Jamzad from Belmont, MA, age ~60
Control profile